Harmony Biosciences (NASDAQ:HRMY – Get Free Report) and Eloxx Pharmaceuticals (NASDAQ:ELOX – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.
Risk and Volatility
Harmony Biosciences has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals has a beta of -1862.26, indicating that its stock price is 186,326% less volatile than the S&P 500.
Earnings & Valuation
This table compares Harmony Biosciences and Eloxx Pharmaceuticals”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Harmony Biosciences | $868.45 million | 2.83 | $158.69 million | $3.08 | 13.70 |
| Eloxx Pharmaceuticals | $6.36 million | 11.20 | -$5.99 million | ($1.54) | -11.45 |
Harmony Biosciences has higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
86.2% of Harmony Biosciences shares are held by institutional investors. Comparatively, 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. 11.0% of Harmony Biosciences shares are held by company insiders. Comparatively, 25.9% of Eloxx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of recent ratings for Harmony Biosciences and Eloxx Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Harmony Biosciences | 1 | 5 | 5 | 0 | 2.36 |
| Eloxx Pharmaceuticals | 1 | 0 | 2 | 1 | 2.75 |
Harmony Biosciences presently has a consensus price target of $47.11, indicating a potential upside of 11.61%. Eloxx Pharmaceuticals has a consensus price target of $41.50, indicating a potential upside of 135.39%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Eloxx Pharmaceuticals is more favorable than Harmony Biosciences.
Profitability
This table compares Harmony Biosciences and Eloxx Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Harmony Biosciences | 18.88% | 20.06% | 14.15% |
| Eloxx Pharmaceuticals | N/A | N/A | N/A |
Summary
Harmony Biosciences beats Eloxx Pharmaceuticals on 10 of the 15 factors compared between the two stocks.
About Harmony Biosciences
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.
Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
